Heidelberg Pharma Reports on First Half-Year 2022
- First clinical trial with HDP-101 in multiple myeloma on track, third cohort in preparation
- Signing of a strategic partnership with Huadong Medicine with an overall deal volume of up to one billion US dollars and an investment agreement of up to EUR 105 million; rights issue of up to EUR 80 million to be launched in August
- Significantly increased sales due to license payment from Huadong
Heidelberg Pharma AG published today its financial report on the first six months of 2022
(1 December 2021 – 31 May 2022).